Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors
NCT ID: NCT01074320
Last Updated: 2015-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2010-02-28
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: We will prospectively assess musculoskeletal symptoms due to treatment with aromatase inhibitors. Post-menopausal women beginning AI treatment for hormone responsive breast cancer will be invited to join this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast cancer patients on AIs
Breast cancer patients beginning Aromatase Inhibitor therapy
Other
Observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Other
Observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hormone-receptor positive cancer (either ER+ or PR+ or both),
* Prescribed and have agreed to take exemestane, anastrazole or letrozole,
* Have completed initial treatment of surgery, RT, and/or chemotherapy,
* Are post-menopausal,
* No previous history of aromatase inhibitor therapy for invasive breast cancer,
* Have signed the consent form.
Exclusion Criteria
* Unable to read or understand English,
* History of psychiatric disability affecting informed consent or compliance with study procedures.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HealthPartners Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen K Swenson, RN, PhD
Role: PRINCIPAL_INVESTIGATOR
HealthPartners Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Memorial Medical Center
Robbinsdale, Minnesota, United States
Park Nicollet Institute
Saint Louis Park, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, Tsai ML, Shapiro AC. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors. Oncol Nurs Forum. 2013 Nov;40(6):549-57. doi: 10.1188/13.ONF.549-557.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03918-09
Identifier Type: -
Identifier Source: org_study_id